Posted by Michael Wonder on 16 Jun 2023
FDA approves Genentech’s Columvi, the first and only bispecific antibody with a fixed duration treatment for people with relapsed or refractory diffuse large B-cell lymphoma
15 June 2023 - Pivotal study showed durable responses, with a 56% overall response rate, a 43% complete response (remission) rate, and a median duration of response of 1.5 years (18.4 months).
Genentech announced today that the US FDA has approved Columvi (glofitamab-gxbm) for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified or large B-cell lymphoma arising from follicular lymphoma, after two or more lines of systemic therapy.
